JP4257946B2 - 可溶化ヒトインターロイキン18レセプターα,その測定方法,測定用キット及び医薬組成物 - Google Patents
可溶化ヒトインターロイキン18レセプターα,その測定方法,測定用キット及び医薬組成物 Download PDFInfo
- Publication number
- JP4257946B2 JP4257946B2 JP2005512489A JP2005512489A JP4257946B2 JP 4257946 B2 JP4257946 B2 JP 4257946B2 JP 2005512489 A JP2005512489 A JP 2005512489A JP 2005512489 A JP2005512489 A JP 2005512489A JP 4257946 B2 JP4257946 B2 JP 4257946B2
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- human
- antibody
- shil
- solubilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000961065 Homo sapiens Interleukin-18 receptor 1 Proteins 0.000 title claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 238000000034 method Methods 0.000 title description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 102000003810 Interleukin-18 Human genes 0.000 claims description 19
- 108090000171 Interleukin-18 Proteins 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 3
- 235000012012 Paullinia yoco Nutrition 0.000 claims 3
- 102000005962 receptors Human genes 0.000 description 39
- 108020003175 receptors Proteins 0.000 description 39
- 102000004557 Interleukin-18 Receptors Human genes 0.000 description 36
- 108010017537 Interleukin-18 Receptors Proteins 0.000 description 36
- 241000699666 Mus <mouse, genus> Species 0.000 description 36
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 34
- 102000043959 human IL18 Human genes 0.000 description 34
- 210000002966 serum Anatomy 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 15
- 230000009261 transgenic effect Effects 0.000 description 15
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 208000029523 Interstitial Lung disease Diseases 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 238000001042 affinity chromatography Methods 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 4
- 101000960949 Mus musculus Interleukin-18 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 description 3
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 108090000426 Caspase-1 Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 101000961064 Mus musculus Interleukin-18 receptor 1 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 101150087698 alpha gene Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
(Y)1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなりかつ当該可溶化ヒトIL−18レセプターαと同じ活性を有するタンパク質
(x)ヒトIL−18レセプターα遺伝子
(y)1若しくは数個の塩基が欠失、置換若しくは付加された塩基配列からなりかつ当該可溶化ヒトIL−18レセプターαと同じ活性を有するタンパク質をコードする遺伝子
(a)H44マウス抗ヒトIL−18レセプターαモノクローナル抗体と同じエピトープを認識し得る、マウス抗ヒトIL−18レセプターαモノクローナル抗体
(a1)H44マウス抗ヒトIL−18レセプターαモノクローナル抗体
(a2)MAB840マウス抗ヒトIL−18レセプターαモノクローナル抗体
(a3)117−10Cマウス抗ヒトIL−18レセプターαモノクローナル抗体
(B)抗ヒトIL−18レセプターαポリクローナル抗体
(b)ラビット抗ヒトIL−18レセプターαポリクローナル抗体
(1)抗ヒトIL−18レセプターαモノクローナル抗体
(2)抗ヒトIL−18レセプターαポリクローナル抗体
(a2)MAB840マウス抗ヒトIL−18レセプターαモノクローナル抗体(R&D Systems社製,Minneapolis,MN,USA,以下、MAB840マウス抗hIL−18Rαと記載する。)
(a3)117−10Cマウス抗ヒトIL−18レセプターαモノクローナル抗体(Hayashibara Biochemical Laboratories Inc.社製,Okayama,Japan,以下、117−10Cマウス抗hIL−18Rαと記載する。)
第二次抗体に、ビオチンを結合させておき、サンドイッチ法の実施後に、ストレプトアビジン結合西洋ワサビペルオキシダーゼを添加し、ビオチンにアビジンを結合させる。西洋ワサビペルオキシダーゼの酵素基質を加え、その酵素活性を測定することで、サンドイッチ法により捕捉された可溶化ヒトIL−18レセプターαを測定する。
このほか、第二次抗体の標識には、公知の放射性アイソトープ、酵素、蛍光物質、化学発光物質,着色物質等を利用することもできる。
自己免疫疾患としては、関節リュウマチ,間質性肺炎,膠原病等が挙げられる。
PBS緩衝液に溶解した4μg/mlのH44マウス抗hIL−18Rαを、ELISA plate(Nunc製)に100μl/well分注し、4℃で一晩置き、第一次抗体であるH44マウス抗hIL−18Rαを、プレートに固層化した後、0.5%のTwin20(界面活性剤)を含むPBS緩衝液200μlで2回洗浄した。
H44マウス抗hIL−18Rα抗体をHiTrap NHS−activated HPカラム(Pharmacia Biotech Ab,Uppsala,Sweden)にカップリングしヒト血清をこのアフィニティカラムを用いてアフィニティカラムクロマトグラフィにかけ、親和性を確認した。結合バッファーは10mM phosphate buffer pH6.8,洗浄バッファーは10mM phosphate buffer,50mM NaCl,pH6.8,溶出バッファーは100mM glycine buffer pH2.5,中和バッファーは1M phosphate buffer pH8.0を用いた。ヒト血清サンプルを結合バッファーで2倍希釈し0.45μm filterで濾過し、結合バッファーであらかじめ平衡化したH44マウス抗hIL−18Rα抗体アフィニティカラムにかけた。洗浄バッファーでアフィニティカラムを洗浄する。溶出バッファーをカラムに流し、溶出バッファー1mlごとに50μl中和バッファーの入ったチューブに入れて回収(回収順にFraction番号1,2,3…とする)しUV280nmでモニターした。回収したFractionを4℃でPBS緩衝液で透析した。UV280nmでモニターはFraction番号1−8でそれぞれ0.0687,0.3598,0.7073,0.0949,0.0377,0,0,0だった。透析したFraction番号1−8を、上述のサンドイッチELISA法でshIL−18Rαを測定したところ、<200,1797,1778,1259,<200,<200,<200,<200ng/mlであった。つまりFraction番号2,3,4にshIL−18Rαが存在することが確認できた。このようにヒト血清から採取したshIL−18Rαは、H44マウス抗hIL−18Rα抗体アフィニティカラムクロマトグラフィにかけて、親和性を確認した。
上記で透析したFraction番号1−8を、H44マウス抗hIL−18Rα抗体を用いてウェスタンブロッティングで解析した。図1に示すようにFraction番号2,3,4に約60kDaの分子量にH44マウス抗hIL−18Rα抗体が認識するshIL−18Rαの存在が確認された(Fraction番号2,4のものも、添付図面では、影が薄いが確認されている)。この結果は上記のアフィニティカラムクロマトグラフィ、サンドイッチELISA法の結果と一致した。以上の結果から、血清に確かにshIL−18Rαが存在していることが、確認された。
(動物モデルにおける、可溶化IL−18Rαの過剰発現誘導)
図2の様にVA−hCD2 vector(Zhumabekov,Journal of Immunological Methods,185(1995),133−140)のSnaBIサイトにマウスIL−18RαのcDNA1.6Kbを挿入し、KpnI/NotIで切り出しC57BL/6(B6)マウスの受精卵に常道に従い注入した。トランスジェニック(TG)マウスをNo.17,27,51,56の4ライン樹立した。この4ラインの10週齢のTGマウスとコントロールwild type(WT)B6マウス(WT#1,WT#2)から脾細胞を取り出し2x106個/mLの細胞密度で10%FCSを加えたRPMI−1640で浮遊した。
抗マウスCD3抗体(1μg/mL),ヒトIL−2(200U/mL),マウスIL−18(200ng/mL),ヒトIL−2(200U/mL)プラスマウスIL−18(200ng/mL)の存在下で18時間培養しIFN−γをELISAキット(R&D社製)で測定した。図3に示すようにWTに比べTGマウスの脾細胞は著明にヒトIL−2(200U/mL)プラスマウスIL−18(200ng/mL)に反応しIFN−γを産生した。
また抗IL−18Rα抗体を用いた膜表面抗原解析でTGマウスはWTマウスに比べリンパ球上にIL−18Rαを強く発現した。
可溶性IL−18Rα受容体を、我々が樹立したELISA法で測定すると、WTマウスの血清では、限界希釈法(limiting dilution method)で測定しても検出限界以下であった。一方、TGマウスの血清を限界希釈法ではx4希釈以上で測定すると、可溶性IL−18Rα受容体の検出が可能であった。つまり、可溶性IL−18α受容体はTGマウスの血清中に大量に存在していた。
1.IL−18に反応可能なIL−18受容体αを過剰に発現し
2.その一部が可溶化して
3.血清中に可溶性IL−18受容体αが大量に存在
することを証明している。
以後の実験にはライン番号51を用いた。以下、CD2−IL−18Rα#51とする。
8から11週齢の雌のTGマウス(CD2−IL−18Rα#51)及びコントロールwild type B6マウスを各10匹ずつ用いた。グラム陰性菌大腸菌由来のlipopolysaccalide(LPS)(E.coli serotype o55:B5 catalog No.L4005,Sigma[St.Louise,MO])40μg/g体重をday 1に腹腔内投与した。図4に示すようにLPSに対する感受性はTGマウスの方がWTマウスより低い。つまりTGマウスはLPSに対し抵抗性を持った。この結果は過剰の可溶性IL−18受容体は生体で菌由来の毒素(endotoxin,exotoxin)に対し治療効果を持つことが判明した。
6週齢の雌のTGマウス(CD2−IL−18Rα#51)及びコントロールwild type B6マウス各5匹にBLM(ブレオマイシン,bleomycin)2mgをday 1に腹腔内投与した。更にBLM 2mgをday8に腹腔内投与した。Day28でマウスの肺を20%ホルマリンで還流し固定した。作製したパラフィンブロックはHE染色を行った。WTマウス(図5,左)に比べTGマウス(図5,右)は、BLMによる肺障害(間質性肺炎、肺線維症)を顕著に抑制した。この結果は、過剰の可溶性IL−18受容体は肺障害に対し治療効果を持つことを示している。
Claims (4)
- 下記(X)又はこれをコードする遺伝子からなる群から選択される一種以上を有効成分として含むことを特徴とする、医薬組成物。
(X)可溶化ヒトインターロイキン18レセプターα - 下記(X)又はこれをコードする遺伝子からなる群から選択される一種以上を有効成分として含むことを特徴とする、インターロイキン18に起因する疾患の予防又は治療剤。
(X)可溶化ヒトインターロイキン18レセプターα - 下記(X)又はこれをコードする遺伝子からなる群から選択される一種以上を有効成分として含むことを特徴とする、肺障害の予防又は治療剤。
(X)可溶化ヒトインターロイキン18レセプターα - 下記(x)を有効成分として含むことを特徴とする、医薬組成物。
(x)ヒトインターロイキン18レセプターα遺伝子
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003282375 | 2003-07-30 | ||
JP2003282375 | 2003-07-30 | ||
PCT/JP2004/010621 WO2005012352A1 (ja) | 2003-07-30 | 2004-07-26 | 可溶性ヒトインターロイキン18レセプターα,その測定方法,測定用キット及び医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2005012352A1 JPWO2005012352A1 (ja) | 2008-01-17 |
JP4257946B2 true JP4257946B2 (ja) | 2009-04-30 |
Family
ID=34113776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005512489A Active JP4257946B2 (ja) | 2003-07-30 | 2004-07-26 | 可溶化ヒトインターロイキン18レセプターα,その測定方法,測定用キット及び医薬組成物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20060241036A1 (ja) |
JP (1) | JP4257946B2 (ja) |
WO (1) | WO2005012352A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
JP5595632B2 (ja) * | 2004-07-16 | 2014-09-24 | 敦生 関山 | Il−18レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物 |
JP5813114B2 (ja) | 2010-08-25 | 2015-11-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Il−18r1に対する抗体およびその使用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11100400A (ja) * | 1996-12-26 | 1999-04-13 | Hayashibara Biochem Lab Inc | インターロイキン−18受容体蛋白質 |
US6087116A (en) * | 1997-03-12 | 2000-07-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18 (IL-18) receptor polypeptides and their uses |
JP3538616B2 (ja) * | 2000-04-25 | 2004-06-14 | 友昭 星野 | 間質性肺炎治療薬および当該疾病の動物モデルの作成方法並びにそれを用いるスクリーニング方法 |
-
2004
- 2004-07-26 US US10/566,269 patent/US20060241036A1/en not_active Abandoned
- 2004-07-26 JP JP2005512489A patent/JP4257946B2/ja active Active
- 2004-07-26 WO PCT/JP2004/010621 patent/WO2005012352A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20060241036A1 (en) | 2006-10-26 |
JPWO2005012352A1 (ja) | 2008-01-17 |
WO2005012352A1 (ja) | 2005-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11000566B2 (en) | Compositions and methods for modulating the immune system | |
Terato et al. | Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen | |
JP2008517922A5 (ja) | ||
US20090214549A1 (en) | Antigenic Epitopes Of Inteleukin-21, Related Antibodies And Their Use In Medical Field | |
JP2002513768A (ja) | Gdf−8の阻害による糖尿病の処置法 | |
KR20160044045A (ko) | 염증성 질환에서 il-18 결합 단백질(il-18bp) | |
JP5153114B2 (ja) | 新規のアルツハイマー病検出方法 | |
JP2010263889A (ja) | サイトカインレセプター鎖 | |
WO2001070817A1 (fr) | Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant | |
JP2009137986A (ja) | 炎症性障害を治療するための組成物及び方法 | |
Shi et al. | IL‐22 produced by Th22 cells aggravates atherosclerosis development in ApoE−/− mice by enhancing DC‐induced Th17 cell proliferation | |
JP4257946B2 (ja) | 可溶化ヒトインターロイキン18レセプターα,その測定方法,測定用キット及び医薬組成物 | |
JPH02479A (ja) | snRNP−A抗原及びそのフラグメント | |
US20060088501A1 (en) | Duffy antigen receptor for chemokines and use thereof | |
CN112368294B (zh) | 用于治疗风湿性关节炎的肽以及其用途 | |
JPWO2017065203A1 (ja) | イヌアトピー性皮膚炎の治療及び診断のために用いる抗イヌtarc抗体 | |
US20020137107A1 (en) | Method for identifying agents which modulate chemokine "MEC"-induced functions of CCR3 and/or CCR10 | |
Kanai et al. | Induction and natural occurrence of serum nucleosomal DNA in autoimmune MRL/lpr/lpr mice: its relation to apoptosis in the thymus | |
JPH06503647A (ja) | ヒトホスホリパーゼ活性化タンパク質および慢性関節リウマチの診断の方法 | |
US7662375B2 (en) | Use of glucose-6-phosphate isomerase and antibodies thereto for the diagnosis and therapy of arthritis, and test of anti-arthritic compounds | |
EP1171157B1 (en) | Use of glucose-6-phospate isomerase and antibodies thereto for the diagnosis and therapy of arthritis, and test of anti-arthritic compounds | |
JPH0767689A (ja) | 抗ld78ポリペプチドモノクローン抗体 | |
Khan et al. | Alterations of cell adhesion molecules in human glomerular endothelial cells in response to nephritis-associated plasminogen receptor | |
JP2005104936A (ja) | イヌtarc抗体 | |
JP2005532793A (ja) | 微生物付着を阻害するための融合ポリペプチドおよび方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081007 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081111 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081209 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081216 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120220 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4257946 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150220 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |